Hantz Financial Services Inc. Has $10.59 Million Stake in Medtronic plc (NYSE:MDT)

Hantz Financial Services Inc. trimmed its position in shares of Medtronic plc (NYSE:MDT) by 3.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 117,573 shares of the medical technology company’s stock after selling 4,306 shares during the period. Hantz Financial Services Inc.’s holdings in Medtronic were worth $10,585,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of MDT. Fortitude Family Office LLC acquired a new position in shares of Medtronic in the third quarter valued at $27,000. Highline Wealth Partners LLC acquired a new position in shares of Medtronic in the third quarter valued at $27,000. Darwin Wealth Management LLC acquired a new position in shares of Medtronic in the third quarter valued at $27,000. Lynx Investment Advisory acquired a new position in shares of Medtronic in the second quarter valued at $28,000. Finally, J. Stern & Co. LLP acquired a new position in shares of Medtronic in the third quarter valued at $30,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MDT has been the subject of a number of recent research reports. Wells Fargo & Company reduced their target price on shares of Medtronic from $106.00 to $98.00 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Stifel Nicolaus boosted their target price on shares of Medtronic from $85.00 to $87.00 and gave the company a “hold” rating in a research report on Wednesday, August 21st. Evercore ISI boosted their target price on shares of Medtronic from $100.00 to $104.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays boosted their target price on shares of Medtronic from $105.00 to $109.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Royal Bank of Canada raised shares of Medtronic from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $98.00 to $105.00 in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $95.27.

Medtronic Stock Up 0.7 %

MDT stock opened at $86.27 on Friday. The stock has a market capitalization of $110.62 billion, a P/E ratio of 26.38, a price-to-earnings-growth ratio of 2.44 and a beta of 0.84. The company has a current ratio of 1.84, a quick ratio of 1.39 and a debt-to-equity ratio of 0.51. Medtronic plc has a 12 month low of $75.96 and a 12 month high of $92.68. The firm has a 50-day moving average price of $88.75 and a 200-day moving average price of $84.97.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The company had revenue of $8.40 billion during the quarter, compared to the consensus estimate of $8.27 billion. During the same quarter in the prior year, the firm posted $1.25 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Medtronic plc will post 5.46 EPS for the current fiscal year.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.